A pivotal phase III trial of edasalonexent in ambulatory patients with Duchenne Muscular Dystrophy regardless of mutation type
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Edasalonexent (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- 09 Nov 2017 According to a Catabasis Pharmaceuticals media release, the company is planning to initiate the trial in first half of 2018.
- 04 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Jan 2018, according to a Catabasis Pharmaceuticals media release.
- 30 Nov 2016 New trial record